Related Experiment Video
Updated: Aug 20, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
Published on: November 10, 2017
The effect of simvastatin therapy on hemorheological profile in coronary heart desease (CHD) patients
Alexei V Muravyov1, Vladimir V Yakusevich, Larisa Surovaya
1Department of Medicine and Biology, University of Yaroslavl, 150000 Yaroslavl, Russia.
Insights
Statin therapy for hypercholesterolemia improved red blood cell (RBC) aggregation and rigidity, key microrheological factors. However, macro-rheological parameters like blood viscosity remained unchanged in patients with coronary heart disease (CHD).
Area of Science:
- Cardiovascular Medicine
- Hematology
- Pharmacology
Background:
- Hypercholesterolemia is a major risk factor for coronary heart disease (CHD).
- Lipid-lowering therapy with statins is standard for managing hypercholesterolemia.
- The hemorheological effects of statins, particularly on red blood cell (RBC) properties, require further investigation.
Purpose of the Study:
- To investigate the impact of simvastatin therapy on hemorheological parameters in patients with CHD and hypercholesterolemia.
- To differentiate the effects of lipid-lowering therapy on macro- and microrheological parameters.
Main Methods:
- Twenty female patients with CHD and hypercholesterolemia received simvastatin (10-20 mg/day) for eight weeks.
- Hemorheological measurements included plasma viscosity, whole blood viscosity (high and low shear), hematocrit, RBC aggregation, and RBC rigidity.
- Measurements were taken before and after the eight-week treatment period.
Main Results:
- Simvastatin significantly reduced total cholesterol, triglycerides, and LDL-cholesterol (p<0.05).
- No significant changes were observed in plasma viscosity or whole blood viscosity.
- Significant decreases in RBC aggregation and RBC rigidity were noted post-treatment.
Conclusions:
- Lipid-lowering therapy with simvastatin primarily impacts microrheological parameters, specifically reducing RBC aggregation and improving RBC deformability.
- The rheological benefits of statins in CHD patients with hypercholesterolemia are mainly related to cellular-level changes rather than bulk blood flow properties.
Abstract:
This study was designed to examine changes of hemorheological parameters in patients with CHD and hypercholesterolaemia (wide range of plasma total cholesterol level from 5.6 to 9.8 mmol.l-1) subjected to lipid lowering therapy with statins (simvastatin, 10.0-20.0 mg/day, dosage was dependent on an initial level of total cholesterol). Twenty female subjects were enrolled in this research program. Both prior to and following drug treatment for eight weeks, hemorheological measurements included plasma viscosity, high and low shear whole blood viscosity, hematocrit, RBC aggregation and rigidity. Treatment with simvastatin significantly (p<0.05) reduced total cholesterol, total triglycerides and low-density lipoprotein cholesterol (LDL-C). However, the hemorheological effects of lipid lowering therapy differed markedly between macro- and microrheological groups of parameters: plasma and whole blood viscosity were not significantly changed whereas RBC aggregation and its rigidity were decreased significantly after statin treatment. These results thus suggest that the rheologic effect of lipid lowering therapy concerned mainly the microrheological parameters: red cell aggregation and deformability.
Related Concept Videos
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Atherosclerosis III: Management
Coronary Artery Disease V: Interprofessional Care
Coronary Artery Disease IV: Preventive Measures
Blood Studies for Cardiovascular System III: Serum Lipid Profile
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
Rheumatic Heart Disease III: Medical Management